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Abstract
Background: Childhood hospitalization related to asthma remains at historically high levels, and its incidence is on the
rise world-wide. Previously, we have demonstrated that aldose reductase (AR), a regulatory enzyme of polyol pathway,
is a major mediator of allergen-induced asthma pathogenesis in mouse models. Here, using AR null (AR
-/-)m i c ew e
have investigated the effect of AR deficiency on the pathogenesis of ragweed pollen extract (RWE)-induced allergic
asthma in mice and also examined the efficacy of enteral administration of highly specific AR inhibitor, fidarestat.
Methods: The wild type (WT) and AR
-/- mice were sensitized and challenged with RWE to induce allergic asthma. AR
inhibitor, fidarestat was administered orally. Airway hyper-responsiveness was measured in unrestrained animals using
whole body plethysmography. Mucin levels and Th2 cytokine in broncho-alveolar lavage (BAL) were determined using
mouse anti-Muc5A/C ELISA kit and multiplex cytokine array, respectively. Eosinophils infiltration and goblet cells were
assessed by H&E and periodic acid Schiff (PAS)-staining of formalin-fixed, paraffin-embedded lung sections. T regulatory
cells were assessed in spleen derived CD4
+CD25
+ Tc e l l sp o p u l a t i o n .
Results: Deficiency of AR in mice led to significantly decreased PENH, a marker of airway hyper-responsiveness,
metaplasia of airway epithelial cells and mucus hyper-secretion following RWE-challenge. This was accompanied by a
dramatic decrease in infiltration of eosinophils into sub-epithelium of lung as well as in BAL and release of Th2
cytokines in response to RWE-challenge of AR
-/- mice. Further, enteral administration of fidarestat significantly prevented
eosinophils infiltration, airway hyper-responsiveness and also markedly increased population of T regulatory (CD4
+CD25
+FoxP3
+) cells as compared to RWE-sensitized and challenged mice not treated with fidarestat.
Conclusion: Our results using AR
-/- mice strongly suggest the role of AR in allergic asthma pathogenesis and
effectiveness of oral administration of AR inhibitor in RWE-induced asthma in mice supports the use of AR
inhibitors in the treatment of allergic asthma.
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Background
In spite of the identification of several factors associated
with the development of allergic airway inflammation, a
clear causative factor or mediator remains elusive.
Asthma attacks are characterized by airway inflammation
and narrowing leading to typical symptoms such as
shortness of breath, cough, wheezing and chest tightness
[ 1 , 2 ] .T h ea t t a c k sc o u l db ec a u s e db yv a r i e ds t i m u l is u c h
as allergens, including tree and grass pollens, dust mites,
pet’s hairs and dander, infections, exercise, sudden
weather change, and environmental pollutants and irri-
tant such as tobacco smoke [3,4]. The severity could vary
from mild to life-threatening attacks. Although asthma
develops at different stages of life, it is one of the leading
chronic childhood disease (9.3% prevalence) and major
cause of disability in children in the United States [5].
Based on the 2008 NHIS sample, it was estimated that
38.4 million Americans, or 128.5 per 1,000 persons, had
been diagnosed with asthma by a health professional
within their lifetime [5].
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onmental tobacco smoke, particulate matter, oxides of
nitrogen, ozone, and repeated respiratory virus exposures
that induce and/or augment reactive oxygen species (ROS)
in the airways have been identified [6-8]. Cellular oxidative
stress induced by ROS plays a fundamental role in inflam-
mation through the activation of inflammatory signals
which activate stress kinases such as ERK1/2, p38 and
JNK, which in turn activate redox-sensitive transcription
f a c t o r ss u c ha sN F - B that transcribe pro-inflammatory
genes [9-12]. We have recently demonstrated that ROS-
derived lipid aldehydes - glutathione (GSH) conjugates
and their metabolic products are mediators of redox sensi-
tive signaling. Aldose reductase (AR), an enzyme that
reduces glucose to sorbitol in the polyol pathway, has
been shown to efficiently reduce lipid aldehydes and their
GSH conjugates (Km lipid aldehydes 10-30 μMa n dK m
g l u c o s e~ 5 0m M )[ 1 3 ] .F u r t h e r ,w eh a v es h o w nt h a t
reduced product of lipid aldehyde-GSH conjugate could
activate NF-B and AP-1 via PLC/PKC/MAPK pathway
[14,15]. Inhibition of AR significantly decreases the activa-
tion of these kinases and transcription factors, which
results in decreased inflammation caused by various sti-
muli including high glucose, cytokines, growth factors,
allergens and carcinogens.
Although, current regimen of asthma therapy, which
includes corticosteroids in the form of inhalers, aims at
reducing the inflammation, the attacks and/or exacerba-
tion are not prevented. Various studies have demonstrated
that antioxidants or ROS scavengers could reduce inflam-
mation in experimental models, so do the inhibitors of the
specific signaling kinases and could be critical targets in
the amelioration of asthma [16-21]. However, these
approaches have not resulted in the cure for asthma.
Therefore, identification of novel targets and approaches
to prevent or treat asthma is important. We have recently
shown that AR could be a novel target to prevent or ame-
liorate inflammation and AR inhibitors could be developed
as potential anti-inflammatory drugs [22,23]. Further, we
have shown that inhibition or genetic ablation of AR could
prevent allergen- or bacterial endotoxin-induced inflam-
mation in human airway epithelial cells [24,25]. Similarly,
administration of AR inhibitors to allergen-sensitized mice
prior to allergen challenge prevented eosinophils infiltra-
tion in the lung, release of Th2 cytokines and chemokines
and allergen associated hyper-responsiveness [24,25].
These results suggest that AR could be an important med-
iator of airway inflammation in allergic asthma and thus a
novel molecular target to treat asthma. However, to
unequivocally confirm that effects of AR inhibitors are
specific to airway inflammation and not due to off-target
effects, here we have used AR gene deletion approach by
using AR null (AR
-/-) mice and also examined the efficacy
of a very potent and specific AR inhibitor, fidarestat
[26,27], via enteral (oral) administration as opposed to par-
enteral in previous studies.
The results shown here demonstrate that RWE sensiti-
zation and challenge increased airway resistance, mucus
hypersecretion, eosinophils infiltration and inflammatory
cytokines and chemokines in wild-type (WT) mice and
these changes were significantly decreased in AR
-/- mice.
Further, oral administration of fidarestat efficiently and
significantly decreased RWE-induced inflammatory cells
infiltration and airway hyper-responsiveness and increased
CD4
+CD25
+FoxP3
+ T regulatory cells (Tregs) population
as compared to mice not treated with fidarestat. These
results strongly support our hypothesis that AR is a key
mediator of airway inflammation in RWE-induced allergic
asthma model and suggest the effectiveness of oral AR
inhibitor treatment for allergic asthma.
Methods
Animals
Approximately 6-8 weeks old Balb/c mice were purchased
from Harlan Sprague-Dawley (San Diego, CA, USA) and
used for experiments with the AR inhibitor. AR null (AR
-/-
) mice on C57BL/6 genetic background, were bred and
maintained in a pathogen-free condition in the animal
resource center at the University of Texas Medical Branch
at Galveston (UTMB), TX, USA and were used for all
knockout studies and showed no complications except for
slightly increased urination [28]. The animals were main-
tained under the 12 h light and dark cycles, and were
given food and water ad libitum. All animal experiments
were performed according to the National Institutes of
Health Guidelines for Care and Use of Experimental Ani-
mals and approved by the University of Texas Medical
Branch Animal Care and Use Committee.
Sensitization and challenge of animals
T h em i c ew e r es e n s i t i z e da n dc h a l l e n g e dw i t hR W E
(Greer’s laboratory; Lenoir, NC) as described by us
previously [24]. Briefly, mice were sensitized with two
intraperitoneal administrations of endotoxin-free RWE
150 μg/100 μl, combined with alum adjuvant in a 3:1 ratio,
on days 0 and 4. In fidarestat (obtained as a gift chemical
from Sanwa Kagaku Kenkyusho Co. Ltd., Nagoya, Japan)
-treated groups, animals received the drug either by gavage
(b.i.d.) or in drinking water ad-libitum so that they received
a total of 200 μg fidarestat per day (estimated; based upon
daily water consumption per mouse) starting on day 9. On
day 11, mice (n = 6) were challenged intranasally with
RWE (100 μg) dissolved in 50 μl of PBS. Control groups of
mice were challenged with equivalent volumes of PBS.
BAL cytology
To evaluate inflammation, animals from all experimen-
tal groups were euthanized on day 14 with ketamine
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and the lungs were lavaged with two 0.8 ml aliquots of
ice-cold PBS. The cells were collected by centrifugation
(1000 g, for 10 min at 4°C), re-suspended in one ml
PBS and total cell counts were determined [24,25]. The
d i f f e r e n t i a lc e l lc o u n tw a sp erformed on cytocentrifuge
preparations stained with hematoxylin and eosin. The
cell composition in the BAL was evaluated by a pathol-
ogist, blinded to treatment groups, to obtain data for
each lung. The representative fields were photographed
with a Photometrix CoolSNAP Fx camera mounted on
a NIKON Eclipse TE 200 UV microscope.
Histo-pathology of the lungs
The lungs were lavaged with and fixed in 4% buffered-
formaldehyde followed by paraffin embedding and sec-
tioning to 5 μm thickness at our histology core facility
(Research histology Core, UTMB, Galveston). The histo-
pathological examination was performed on the H&E
stained sections using a Photometrix CoolSNAP Fx cam-
era mounted on a NIKON Eclipse TE 200 UV micro-
scope. The representative fields were photographed and
presented (n = 6).
Periodic Acid Schiff (PAS) Staining
Metaplasia of the lung epithelial cells was determined by
PAS-staining of formalin-fixed, paraffin-embedded lung
sections [29]. The stained sections were observed as above
and representative fields were photographed with a Photo-
metrix CoolSNAP Fx camera mounted on a NIKON
Eclipse TE 200 UV microscope
Determination of Mucin by ELISA
Muc5A/C level in the BAL was determined by ELISA
using commercially available mouse anti-Muc5A/C ELISA
essentially as described by the manufacturer (Cosmo Bio
USA; Carlsbad, CA).
Determine of airway hyper-responsiveness
Airway responsiveness was measured in unrestrained,
conscious mice 3 days after the RWE-challenge [24]. The
mice were placed in a barometric plethysmographic
chamber, baseline readings were taken and averaged for
3 min. Aerosolized methacholine in increasing concen-
trations (from 10 to 100 mg/ml) were nebulized through
an inlet of the main chamber for 3 min. Readings were
taken and averaged for 3 min after each nebulization and
PENH was determined. PENH was calculated as (expira-
tory time/relaxation time
-1) × (peak expiratory flow/peak
inspiratory flow) according to the manufacturers’ proto-
col. PENH correlates with pulmonary airflow resistance
or obstruction and was used as a measure of airway
responsiveness to methacholine.
Immunofluorescence staining and FACS analysis
Anti mouse Tregs detection Kit (Cat# 130-094-164) from
Miltenyi biotech (Auburn, CA) was used to determine the
percentage of FoxP3
+ cells in CD4
+/CD25
+ T cell popula-
tion. The mouse spleenocytes were isolated and first sur-
face stained with FITC-labeled anti-mouse CD4 and
PE-labeled anti-mouse CD25 mAb per standard protocol.
These cells were subsequently stained with APC-labeled
antimouse-FoxP3 mAb or rat IgG2a nonspecific isotype
control mAb, according to the manufacturer’s recommen-
dations (Miltenyi Biotech) and hundred thousand events
from each sample were analyzed by flow cytometry using
the LYSIS II software (FACScan, BD Pharmingen) and
presented as the percent population of either CD4
+/FoxP3
+ or CD25
+/FoxP3
+ T cells.
Statistical analysis
The data presented are mean ± SD and p values were
determined by unpaired, two-tailed Student’stt e s ta n d
analyzed by ANOVA. The p values less than 0.05 were
considered statistically significant.
Results
AR deficiency protects against RWE-induced airway
hyper-responsiveness in mice
Since inflammatory changes in allergic asthma lead to
blockage of airway passages an dc a u s ea i r w a yr e s i s t a n c e
leading to hyper-responsiveness, we first subjected the
RWE-sensitized and challenged mice to whole body
unrestrained plethysmography and quantitatively mea-
sured airway responsiveness in response to methacholine
inhalation. As shown in Figure 1, in WT mice, PENH ele-
vated dose-dependently in response to methacholine
challenge as compared to control mice treated with PBS
alone, whereas in AR
-/- mice sensitized and challenged
with RWE, the PENH values were significantly (~70%;
p < 0.01) less compared to RWE-sensitized and chal-
lenged WT mice. These results indicate that deletion of
AR significantly prevented the patho-physiological effects
of allergic asthma in mice.
AR deficiency protects against RWE-induced mucous cell
metaplasia and mucin hyper-secretion in mice lung
Excessive mucus secretion is known to cause airway
obstruction, which is one of the main patho-physiological
characteristic of allergic asthma. Inhibition of mucous
cell metaplasia and subsequent mucin hypersecretion
could minimize allergic attacks and exacerbation in sus-
ceptible individuals [30,31]. Therefore, to investigate if
AR deficiency affects the mucin levels in mice, we mea-
sured the levels of Muc5A/C in the BAL fluid by ELISA.
We found that mucin levels increased approximately 4-
folds in RWE-challenged WT mice as compared to WT
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-/- mice
the levels of Muc5A/C were significantly (p < 0.0003) less
(Figure 2A). Similarly, PAS-staining of the lung sections
showed increased number of PAS positive cells in WT
mice than in AR
-/- mice (Figure 2B).
AR deficiency protects against RWE-induced infiltration of
eosinophils in mice lung
Accumulation of inflammatory cells in BAL fluid and
infiltration into lung sub-epithelial spaces in response to
allergens is indicative of airway inflammation. Since
pathological responses of RWE-challenge i.e. airway
resistance and mucus secretion were significantly pre-
vented in AR
-/- mice, we next examined the effect of AR
deficiency on eosinophils infiltration, main characteristic
feature of allergic asthma, in the BAL fluid as well as in
the lung. As shown in Figure 3A, and 3B there was a sig-
nificant increase in the number of total cells as well as
Eosinophils in the BAL fluid from the RWE-sensitized
and -challenged WT mice whereas the number was sig-
nificantly less in the BAL of RWE-sensitized and -chal-
lenged AR
-/- mice. The eosinophils in the BAL were
approximately 21% in WT mice when sensitized and
challenged with RWE, whereas in AR
-/- mice significantly
less number of eosinophils (~9%) were observed as com-
p a r e dt o0 %i nb o t h ,W Ta n dA R
-/-,c o n t r o lm i c e .
Further, the percentages of neutrophils in the BAL of
RWE-sensitized and -challenged WT and AR
-/- mice
were 0.33 and 0.13 respectively, while those of lympho-
cytes were 0.19 and 0.15, respectively. Similarly, when
BAL cytospin preparations were compared, there were
more eosinophils in the RWE-challenged WT mice than
in RWE-challenged AR
-/- mice (Figure 3C). Further, peri-
vascular and peri-bronchial inflammation, as determined
by infiltration of eosinophils in these regions of the lung
tissue, in the RWE-challenged AR
-/- mice was markedly
less compared to RWE-challenged WT mice (Figure 4).
These results indicate protective role of AR deficiency in
the RWE-induced inflammation in mice lung.
AR deficiency protects from RWE-induced secretion of
cytokines and chemokines in mice lung
Th2 type cytokines and chemokines play an important
role in the allergic airway disease therefore, we deter-
mined the effect of AR deficiency on the RWE-induced
expression of Th2 type cytokines and chemokines in the
BAL fluid using multiplex cytokine and chemokines
assay. As shown in Table 1, RWE-challenge of the WT
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Figure 1 AR deficiency prevents methacholine-induced airway hyper-responsiveness in RWE-challenged mice.T h ec h a n g e si nP E N H
were measured by whole-body plethysmography. Mice were placed in a barometric plethysmographic chamber and PENH, an index of airway
obstruction, was determined and plotted against the increasing concentration of methacholine. Each data point represents mean±SD of 4 mice
for each group. *p < 0.01 vs. WT-RWE. RWE, ragweed pollen extract; WT, wild-type; BL, base line; PENH, enhanced pause.
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Figure 2 AR deficiency decreases mucin levels and mucous cell metaplasia in airway of RWE-challenged mice. (A) RWE-sensitized WT
and AR
-/- mice were challenged with RWE and 72 h later the lungs were lavaged with cold PBS. The supernantant was used for the
determination of Mucin5A/C using mouse Muc5A/c specific ELISA. The bars represent mean±SD (n = 4) *p = 0.00068 vs. WT Control; **p =
0.00027 vs. WT-RWE. (B) The lungs were harvested, perfused and fixed with 4% paraformaldehyde and embedded in paraffin. The sections were
stained with PAS stain and observed under light microscope and photomicrographs were acquired. A representative photomicrograph from
each group is shown (Magnification 200×) (n = 4). RWE, ragweed pollen extract; WT, wild-type; AR
-/-, aldose reductase null mice.
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Figure 3 AR deficiency prevents accumulation of eosinophils in BAL of RWE-challenged mice. The mice were sensitized and challenged
with PBS or RWE and 72 h later lungs were lavaged and differential cell counts were determined as described in methods. The total cells (A)
and eosinophils (B) per ml BAL fluid are shown as bar diagram. The bars represent mean ± SD (n=4 -6). **p< 0.001. (C) The photomicrograph
showing a representative field of H&E stained preparations from each group of mice (Magnification 200×). Arrowheads point to eosinophils in
BAL cytospin preparation (n = 4-6). RWE, ragweed pollen extract; WT, wild-type; AR
-/-, aldose reductase null mice.
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Cytokine and chemokines WT Control AR
-/- Control WT-RWE AR
-/--RWE
1. IL-1a 1.1 ± 0.5 1.6 ± 1.0 35.2 ± 1.9*** 22.0 ± 3.3
#
2. IL-2 11.0 ± 0.8 12.4 ± 0.7 19.7 ± 3.1* 12.3 ± 2.0
#
3. IL-4 ND
¶ ND
¶ 8.9 ± 0.8* 1.5 ± 0.7
#
4. IL-5 1.6 ± 1.6 6.5 ± 1.5 108.5 ± 18.7** 53.0 ± 4.0
#
5. IL-6 2.4 ± 1.3 3.2 ± 0.4 67.5 ± 12.1** 27.4 ± 2.4
#
6. IL-7 2.4 ± 1.4 2.4 ± 1.3 10.1 ± 0.7** 5.3 ± 0.2
#
7. IL-10 2.1 ± 1.8 1.6 ± 1.6 24.0 ± 3.6** 9.7 ± 4.2
#
8. IL-13 2.4 ± 1.3 3.2 ± 0.5 76.6 ± 6.5* 15.5 ± 2.3
#
9. G-CSF 9.2 ± 1.8 9.5 ± 3.9 842.8 ± 115.4** 239.4 ± 56.0
##
10. IP-10 4.0 ± 1.4 4.8 ± 2.1 79.9 ± 14.8** 24.3 ± 3.9
#
11. MIP-1 ND
¶ 0.05 ±0.03 46.3 ± 2.7*** 24.5 ± 0.5
##
12. KC 2.7 ± 1.7 2.8 ± 1.6 33.1 ± 1.8** 15.6 ± 1.65
##
13. RANTES 0.9 ± 0.1 1.1 ± 0.7 4.4 ± 1.1* 1.9 ± 0.4
#
The levels of cytokines and chemokines in the BAL fluids were measured using the magnetic beads-based multiplex cytokine assay system. Data (pico-gm/mL)
are presented as means ± SD (n = 4).
*p < 0.02 vs. WT control mice; **p < 0.008 vs. WT control mice; ***p<0.0002 vs. unchallenged WT control mice;
#p<0.03 vs. WT-RWE-challenged mice,
##p<0.005
vs. WT-RWE-challenged mice.
¶ND, non-detectable.
WT AR-/-
WT+RWE AR-/-+RWE
Figure 4 AR deficiency blocks inflammatory cells infiltration in RWE-challenged mice lung. Lungs of RWE-sensitized and challenged mice
were lavaged and fixed. The fixed lungs were sectioned and stained with H&E. Arrowheads indicate sites of inflammatory cells infiltration
induced by RWE-challenge (n = 4-6). RWE, ragweed pollen extract; WT, wild-type; AR
-/-, aldose reductase null mice.
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chemokines, especially the levels of Th2 cytokines IL-4,
IL-5, IL-6, IL-7, IL-10 and IL-13, and chemokines such as
G-CSF, IP-10, MIP-1, and KC were significantly elevated
in the WT mice BAL fluid upon RWE challenge. The
levels of these inflammatory markers were significantly
lower in RWE-challenged AR
-/- mice BAL fluid. In WT
as well as AR
-/- control mice there was no significant
alteration in the level of these cytokines and chemokines.
Oral administration of AR inhibitor, fidarestat, prevented
RWE-induced eosinophils infiltration and hyper-reactivity
in mice airway
Next, we tested the efficacy of orally administered, very
potent and specific AR inhibitor, fidarestat, in RWE-
induced asthma in mice. The inhibitor was administered
through oral route either by gavage (b.i.d.) or in drinking
water ad-libitum starting 24 h before challenge and contin-
ued until the end of experiment (200 μg fidarestat per kg
body weight per day). As shown in Figure 5A airway hyper
reactivity in RWE-challenged mice significantly decreased
when mice were administered fidarestat in water ad-libi-
tum or by gavage as compared to RWE-challenged mice
not given fidarestat. Similar pattern was observed when
eosinophils accumulation in BAL fluid was determined
(Figure 5B). Fidarestat administration did not change the
basal airway hyper reactivity in control mice not sensitized
and challenged with RWE (data not included).
Further, various studies have implicated up-regulation of
Tregs in the amelioration of asthma pathogenesis (32-34).
Therefore, we examined whether AR inhibitor affects the
Tregs population in the spleen of RWE-sensitized and
challenged mice. We analyzed the population of Tregs
(CD4
+/FoxP3
+ or CD25
+/FoxP3
+)i ns p l e e n - d e r i v e dT
cells by FACS analysis and found that fidarestat-treatment
of RWE-challenged mice led to elevated levels of Tregs
compared to that of RWE-challenge alone (Figure 6).
Taken together, these findings suggest that AR inhibition
could significantly decrease patho-physiological changes as
it leads to increased percentage of Tregs in the experimen-
tal murine model of RWE-induced asthma.
Discussion
In the present study, we have used AR
-/- mice to investi-
gate the effect of AR deficiency on RWE-induced airway
inflammation. Our results suggest that while in WT mice
RWE-sensitization and -challenge resulted in increased
inflammation as determined by accumulation of eosino-
phils in the lungs and BAL fluid, increased cytokines and
chemokines levels and a dose-dependent increase in
PENH, the AR
-/- mice showed significantly less inflamma-
tion as they had decreased levels of eosinophils, cytokines
and chemokines and airway hyper-responsiveness. Further,
oral administration of fidarestat, significantly decreased
the number of eosinophils and hyper-responsiveness to
methacholine and elevated the levels of Tregs compared
to mice sensitized and challenged with RWE alone.
Although it is premature to speculate the therapeutic
potential of AR inhibitors in allergic asthma, our present
results in mice besides strongly supporting our earlier
results, further suggest that AR inhibitors such as fidare-
stat could be preventive as well as therapeutic in allergic
asthma.
The pathophysiology of asthma is a multi-cellular
event involving airway epithelium, lung fibroblasts and
smooth muscles, resident macrophages and dendritic
cells and infiltrated leukocytes including eosinophils,
neutrophils, and polarized Th2 cells. Besides the fact
that allergic asthma is Th2-mediated pathology, airway
epithelium plays an important role as it gets exposed to
the external allergens first and starts an inflammatory
event that gets further accentuated by other cell types
[35]. The airway epithelium in asthmatics becomes fra-
gile and defective in repair and antioxidant functions
that lead to compromised tight junctions, which results
in greater destruction and loss of epithelial cells leading
to enhanced airway responsiveness. Our results in the
present study demonstrate that AR
-/- mice showed sig-
nificantly decreased airway responsiveness which is in
concert with our earlier findings that AR inhibition pre-
vents allergen-induced epithelial cell loss due to apopto-
sis [24]. Further, decrease in airway responsiveness
could also result from significantly decreased goblet cell
metaplasia in AR
-/- mice airway subsequent to RWE-
challenge (Figure 2), which is in concert with our earlier
observations [29].
Increased oxidative stress due to release of ROS from
cells upon exposure to the oxidants including allergens,
bacterial/viral antigens, cigarette smoke and vehicle
exhaust and particulate matters as well as from the
inflammatory and immune cells in the airway has been
demonstrated [9,36-39]. Increased ROS levels in airway
epithelial cells upon allergen exposure activate redox-
sensitive signaling cascade leading to the activation of
transcription factors such as NF-Ba n dA P - 1w h i c h
transcribe various inflammatory mediator genes and pro-
mote apoptosis [24,25]. Further, release of inflammatory
markers results in epithelial cell loss as well as chemo-
attraction of leukocytes such as mast cells, basophiles,
Eosinophils, neutrophils, T-cells, and macrophages. The
activated inflammatory cells further enhance oxidative
stress by directly releasing ROS such as superoxides and
H2O2 and in addition release inflammatory cytokines,
especially Th2 cytokines that lead to pathogenesis of
allergic asthma. In our study, a significant decrease in
total inflammatory cells, more specifically that of eosino-
phils in BAL and lung sub-epithelium of AR
-/- mice
(Figure 3, and 4) indicates that AR-deficiency results in
Yadav et al. Respiratory Research 2011, 12:145
http://respiratory-research.com/content/12/1/145
Page 7 of 12suppression of allergen-induced activation of airway
epithelium leading to subsequent decrease in inflamma-
tory cells infiltration and release of inflammatory cyto-
kines and chemokines in BAL (Table 1). These evidences
thus strongly suggest the role of AR in the pathogenesis
of allergic asthma.
Subsequent to confirming that AR is indeed involved
in the mediation of allergic asthma, we tested the oral
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Figure 5 AR inhibition by oral administration of fidarestat blocks airway hyper-responsiveness and accumulation of inflammatory cells
in BAL of RWE-challenged mice.( A) The changes in PENH were measured by whole-body plethysmography. Mice were placed in a barometric
plethysmographic chamber and PENH was determined and plotted against the increasing concentration of methacholine. Each data point
represents mean±SD (n = 6). *p < 0.05 and **p< 0.01 vs. RWE, (B) Eosinophils in the BAL fluid were determined 72 h after RWE-challenge and
presented as bar diagram. The bars represent (mean ± SD) eosinophils per ml BAL fluid (n=6). *p < 0.05 and **p< 0.01 vs. RWE. BL, baseline;
RWE, ragweed pollen extract; Fida, fidarestat. PENH, enhanced pause.
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fidarestat, which was administered either by gavage or
in drinking water ad-libitum.An u m b e ro fA Ri n h i b i -
tors including sorbinil, tolrestat, and zenarestat have
undergone clinical trials for diabetic complications and
were found to have several irreversible side-effects [40].
Fidarestat, on the other hand, has undergone phase III
clinical trial for diabetic neuropathy and found to have
no irreversible side effects [41]. The findings in Figure 5
indicate that fidarestat when given to mice orally signifi-
cantly prevented airway hyper-responsiveness and eosi-
nophils infiltration in response to RWE-sensitization
and challenge.
Several investigators have implicated up-regulation of
Tregs in the amelioration of asthma pathogenesis [32,33].
M c G e ea n dA g r a w a l( 2 0 0 9 )h a v ed e m o n s t r a t e dt h a t
Tregs derived from lung and spleen when transferred to
mice sensitized and challenged with cockroach antigen,
they completely reversed airway hyper-responsiveness
and allergic airway inflammation and this effect was long
lasting [34], suggesting protective role of Tregs in allergic
asthma. Therefore, we examined the affect of AR inhibi-
tion on Tregs population in the spleen of RWE-sensitized
and -challenged mice. To our surprise, we observed that
fidarestat-treatment of RWE-challenged mice led to ele-
vated population of Tregs (CD4
+/FoxP3
+ or CD25
+/FoxP3
+) in spleen-derived CD4
+/CD25
+ T cells pool as
compared to RWE alone -challenged mice (Figure 6).
Although these results indicate that inhibition of AR
increased the percentage of Tregs in spleen which could
modify the RWE-induced airway hyper-responsiveness
and inflammation (Figures 5A and 5B), the mechanism of
such upregulation of Tregs by AR inhibition is still
unclear.
Our recent studies have shown that AR, an enzyme
that was contemplated to reduce aldehyde-sugars such as
glucose to corresponding alcohol such as sorbitol and
cause diabetic complications including diabetic neuropa-
thy, retinopathy and nephropathy, in fact more efficiently
catalyzes the reduction of lipid peroxidation-generated
lipid derived-aldehydes such as 4-hydroxynonenal (HNE)
(Km HNE: 10-30 μMV s .K m glucose: 50 mM) [13,42].
HNE and their glutathione conjugates, GS-HNE are
reduced by AR to corresponding alcohols such as dihy-
droxynonene (DHN) or glutathiolated- dihydroxynonene
(GS-DHN) [42]. It is well known that cytokines, chemo-
kines, growth factors, endotoxins, allergens and environ-
mental pollutants cause increased ROS generation in the
biological system, which could oxidize cellular biomole-
cules. Membrane lipids, when oxidized by ROS, form
lipid peroxidation products, such as HNE which are con-
sidered as the biomarkers in the oxidative stress-induced
inflammatory diseases. Increased levels of HNE, found in
the asthmatics lungs, could readily react with cellular glu-
tathione and form GS-HNE conjugates leading to
decrease in reduced glutathione. Decrease in the levels of
GSH along with increased GSSG in BAL fluid has been
reported in asthmatic children and found to be associated
with increased malondialdehyde, 8-isoprostanes, 4-HNE
and H2O2 [43]. It has been shown that under inflamma-
tory conditions the expression of AR increases signifi-
cantly and this increase in expression is not related to
increased glucose levels [44,45]. Thus, low Km of AR for
lipid-aldehydes and their GSH-conjugates and oxidative
stress-induced and glucose-independent increased
expression of AR suggest that AR plays a significant role
in oxidative stress-induced inflammation besides being
an aldehyde detoxifying enzyme. We have demonstrated
that AR-catalyzed reduced product of GSH-lipid alde-
hydes i.e. GS-DHN mediates the activation of redox-sen-
sitive transcription factors NF-B and AP1 via PLC/
PKC/IKK/MAPK pathway that causes inflammation
[14,15], thus inhibition or deficiency of AR should block
the inflammatory signals (Figure 7). Therefore, our
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Figure 6 Oral administration of fidarestat increased the
percentage of FoxP3
+ Tregs in the spleen-derived CD4
+CD25
+
T cells population following RWE-challenge. The spleen-derived
CD4
+CD25
+ T-cells from different groups were stained with FoxP3
antibodies and subjected to FACS analysis. The bars represent (A)
CD25
+FoxP3
+ and (B) CD4
+FoxP3
+ population, data expressed as
mean±SD (n = 5), *p<0.05 vs. RWE; **p<0.01 vs. RWE. RWE, ragweed
pollen extract, Fida, fidarestat.
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Page 9 of 12results present a novel evidence that deficiency of AR sig-
nificantly decreases inflammatory and pathological
changes upon allergen challenge in mice which could be
due to lack of AR-catalyzed mediator of inflammatory
signals in AR
-/- mice.
Conclusions
The present study, by utilizing a knockout animal
model, confirms the role of AR in the mediation of
allergic airway inflammation in mice and also suggests
that oral administration of AR inhibitor, fidarestat,
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Figure 7 Schematic of working mechanismo fA Ri na i r w a yi n f l a m m a t i o n . The ROS generated by different stimuli including pollens,
allergens, growth factors and cytokines are known oxidize membrane lipids to lipid aldehydes such as 4-hydroxynonenal (HNE), which could
readily conjugate with glutathione (GSH) and form GS-lipid aldehydes (e.g. GS-HNE). AR reduces GS-HNE to GS-DHN which activates PLC, PKC
and PI3K which in turn could lead to activation of transcription factors including NF-B, AP-1, and STAT-6 that transcribe various inflammatory
genes. The inflammatory markers propagate the signals in autocrine and/or paracrine fashion and cause airway inflammation and asthma
pathogenesis. AR inhibition blocks this cascade upstream of various kinases and thus prevents inflammation.
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matory changes.
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